| 000 | 01614 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517183058.0 | ||
| 264 | 0 | _c20180627 | |
| 008 | 201806s 0 0 eng d | ||
| 022 | _a1557-8593 | ||
| 024 | 7 |
_a10.1089/dia.2017.0111 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhang, Tingting | |
| 245 | 0 | 0 |
_aObservational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors. _h[electronic resource] |
| 260 |
_bDiabetes technology & therapeutics _c11 2017 |
||
| 300 |
_a675-684 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBlood Glucose _xanalysis |
| 650 | 0 | 4 | _aChina |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemia _xblood |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadverse effects |
| 650 | 0 | 4 |
_aInsulin Detemir _xadverse effects |
| 650 | 0 | 4 |
_aInsulin Glargine _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRegistries |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aJi, Linong | |
| 700 | 1 | _aGao, Yan | |
| 700 | 1 | _aZhang, Puhong | |
| 700 | 1 | _aZhu, Dongshan | |
| 700 | 1 | _aLi, Xian | |
| 700 | 1 | _aJi, Jiachao | |
| 700 | 1 | _aZhao, Fang | |
| 700 | 1 | _aZhang, Heng | |
| 700 | 1 | _aGuo, Xiaohui | |
| 773 | 0 |
_tDiabetes technology & therapeutics _gvol. 19 _gno. 11 _gp. 675-684 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1089/dia.2017.0111 _zAvailable from publisher's website |
| 999 |
_c27742256 _d27742256 |
||